» Articles » PMID: 21251066

Association of Cytotoxic T Lymphocyte Associated Antigen-4 Gene (rs60872763) Polymorphism with Crohn's Disease and High Levels of Serum SCTLA-4 in Crohn's Disease

Overview
Specialty Gastroenterology
Date 2011 Jan 22
PMID 21251066
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Background And Aim: Our aim was to evaluate cytotoxic T lymphocyte associated antigen-4 (CTLA-4) gene polymorphisms in Crohn's disease (CD) and explore soluble CTLA-4 (sCTLA-4) levels in serum of CD patients in central China.

Methods: A total of 126 Chinese CD patients and 300 healthy controls were enrolled in this study. CTLA-4 (AT)n repeat polymorphism was genotyped by a semiautomatic fluorescently labeled polymerase chain reaction (PCR) method, and CTLA-4 -1661A/G and -1722T/C polymorphisms were genotyped by DNA sequencing. Serum sCTLA-4 and C-reactive protein (CRP) levels were determined by enzyme linked immunosorbent assay (ELISA) and immunonephelometry, respectively.

Results: The frequency of 84 bp allele of CTLA-4 (AT)n repeats was lower in CD patients than in the healthy controls (22.2% vs 33.2%, P = 0.001, odds ratio = 0.58, 95% confidence interval: 0.41-0.81). The 84 bp allele carriers of (AT)n repeats were associated with non-stricturing and non-penetrating disease behavior in CD patients (P = 0.007). Serum sCTLA-4 levels were more elevated in CD patients than in the healthy controls (P < 0.001). Among CD patients, serum sCTLA-4 levels were increased in active disease compared with inactive disease (P = 0.015), and were correlated with CRP levels (r = 0.524, P < 0.001). Serum sCTLA-4 levels were higher in CD patients with stricturing disease behavior than in patients with other disease behaviors (P = 0.009).

Conclusions: 84 bp allele of CTLA-4 (AT)n repeat polymorphism was associated with CD in central China. sCTLA-4 levels were highly expressed in CD, especially in active disease, and were correlated with CRP levels and disease behavior in CD patients.

Citing Articles

Co-Inhibitory Molecules - Their Role in Health and Autoimmunity; Highlighted by Immune Related Adverse Events.

Greisen S, Aspari M, Deleuran B Front Immunol. 2022; 13:883733.

PMID: 35784333 PMC: 9243421. DOI: 10.3389/fimmu.2022.883733.


Biomarkers for the Prediction and Diagnosis of Fibrostenosing Crohn's Disease: A Systematic Review.

Steiner C, Berinstein J, Louissaint J, Higgins P, Spence J, Shannon C Clin Gastroenterol Hepatol. 2021; 20(4):817-846.e10.

PMID: 34089850 PMC: 8636551. DOI: 10.1016/j.cgh.2021.05.054.


Soluble CTLA-4 as a favorable predictive biomarker in metastatic melanoma patients treated with ipilimumab: an Italian melanoma intergroup study.

Pistillo M, Fontana V, Morabito A, Dozin B, Laurent S, Carosio R Cancer Immunol Immunother. 2018; 68(1):97-107.

PMID: 30311027 PMC: 11028053. DOI: 10.1007/s00262-018-2258-1.


Ipilimumab-Induced Gastrointestinal Toxicities: A Management Algorithm.

Klair J, Girotra M, Hutchins L, Caradine K, Aduli F, Garcia-Saenz-de-Sicilia M Dig Dis Sci. 2016; 61(7):2132-9.

PMID: 26846115 DOI: 10.1007/s10620-016-4042-4.


Diverse mechanisms regulate the surface expression of immunotherapeutic target ctla-4.

Schneider H, Rudd C Front Immunol. 2014; 5:619.

PMID: 25538704 PMC: 4255484. DOI: 10.3389/fimmu.2014.00619.